PM pheno type actua lly produce d no urin ary sulfoxi de metab olit es.
With respect to diurn al co ntro l, the invo lved enzy mes are downreg ulated du ring the night. As a res ult, the produ ction of sulfoxi de metabol ites is reduced (by 54 .7% [± 15.6 
]).6
Th ese see mingly insigni ficant observations are actua lly vital because recen t wo rk indicates that SCM C functions as a free radica l scavenger' and tha t, in this res pect, the sulfide (parent com pound) is the active species and the su lfoxi de metabol ites (a lready oxidized) are inac tive.
Thu s, administrat ion of SC MC w ill benefit an indi vidual wi th a PM or 1M phenotype more than it wi ll a patient with an EM phenotype . Moreover, in a patient with an EM phenotype, nightt ime intake of the drug should be more beneficial than dayt ime adm inistration . 
